Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

IMPORTANCE: Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known about the activity of anti–programmed cell death lig...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Oncol
Main Authors: Hassan, Raffit, Thomas, Anish, Nemunaitis, John J., Patel, Manish R., Bennouna, Jaafar, Chen, Franklin L., Delord, Jean-Pierre, Dowlati, Afshin, Kochuparambil, Samith T., Taylor, Matthew H., Powderly, John D., Vaishampayan, Ulka N., Verschraegen, Claire, Grote, Hans Juergen, von Heydebreck, Anja, Chin, Kevin, Gulley, James L.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2019
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439847/
https://ncbi.nlm.nih.gov/pubmed/30605211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5428
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים